Literature DB >> 12516559

Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.

Claudia A Daubenberger1, Beatrice Nickel, Carlo Ciatto, Markus G Grütter, Friederike Pöltl-Frank, Laura Rossi, Uwe Siegler, John Robinson, Oscar Kashala, Manuel Elkin Patarroyo, Gerd Pluschke.   

Abstract

Like most other surface-exposed antigens of Plasmodium falciparum, the leading malaria vaccine candidate merozoite surface protein (MSP)-1 contains a large number of dimorphic amino acid positions. This type of diversity is presumed to be associated with parasite immune evasion and represents one major obstacle to malaria subunit vaccine development. To understand the precise role of antigen dimorphism in immune evasion, we have analyzed the flexibility of CD4 T cell immune responses against a semi-conserved sequence stretch of the N-terminal block of MSP-1. While this sequence contains overlapping promiscuous T cell epitopes and is a target for growth inhibitory antibodies, three dimorphic amino acid positions may limit its suitability as component of a multi-epitope malaria vaccine. We have analyzed the CD4 T cell responses in a group of human volunteers immunized with a synthetic malaria peptide vaccine containing a single MSP-143-53 sequence variant. All human T cell lines and HLA-DR- or -DP-restricted T cell clones studied were exclusively specific for the sequence variant used for immunization. Competition peptide binding assays with affinity-purified HLA-DR molecules indicated that dimorphism does not primarily affect HLA binding. Modeling studies of the dominant restricting HLA-DRB1*0801 molecule showed that the dimorphic amino acids represent potential TCR contact residues. Lack of productive triggering of the TCR by MHC/variant peptide ligand complexes thus seems to be the characteristic feature of parasite immune evasion associated with antigen dimorphism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12516559     DOI: 10.1002/1521-4141(200212)32:12<3667::AID-IMMU3667>3.0.CO;2-C

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon.

Authors:  J C Lima-Junior; D M Banic; T M Tran; V S E Meyer; S G De-Simone; F Santos; L C S Porto; M T Q Marques; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2010-02-26       Impact factor: 3.641

2.  Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen.

Authors:  J Andrew Pearce; Tony Triglia; Anthony N Hodder; David C Jackson; Alan F Cowman; Robin F Anders
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 3.  Major Histocompatibility Complex and Malaria: Focus on Plasmodium vivax Infection.

Authors:  Josué da Costa Lima-Junior; Lilian Rose Pratt-Riccio
Journal:  Front Immunol       Date:  2016-01-27       Impact factor: 7.561

Review 4.  Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.

Authors:  Hernando Curtidor; César Reyes; Adriana Bermúdez; Magnolia Vanegas; Yahson Varela; Manuel E Patarroyo
Journal:  Molecules       Date:  2017-12-12       Impact factor: 4.411

Review 5.  Development of designed site-directed pseudopeptide-peptido-mimetic immunogens as novel minimal subunit-vaccine candidates for malaria.

Authors:  José Manuel Lozano; Liliana P Lesmes; Luisa F Carreño; Gina M Gallego; Manuel Elkin Patarroyo
Journal:  Molecules       Date:  2010-12-06       Impact factor: 4.411

6.  Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting.

Authors:  Nitchakarn Noranate; Franck Prugnolle; Hélène Jouin; Adama Tall; Laurence Marrama; Cheikh Sokhna; Marie-Thérèse Ekala; Micheline Guillotte; Emmanuel Bischoff; Christiane Bouchier; Jintana Patarapotikul; Jun Ohashi; Jean-François Trape; Christophe Rogier; Odile Mercereau-Puijalon
Journal:  BMC Microbiol       Date:  2009-10-15       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.